Penumbra Inc Stock News

Polaris Wealth Advisory Group LLC increased its stake in Penumbra, Inc. (NYSE:PEN) by 46.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 5,072 shares of the company’s stock after purchasing an additional 1,604 shares during the quarter. Polaris Wealth Advisory Group LLC’s holdings in […]

Parametric Portfolio Associates LLC raised its stake in Penumbra, Inc. (NYSE:PEN) by 7.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,231 shares of the companys stock after acquiring an additional 2,616 shares during the period. Parametric Portfolio Associates LLC owned about 0.10% []

Royal Bank of Canada lifted its stake in Penumbra, Inc. (NYSE:PEN) by 51.6% during the second quarter, Holdings Channel reports. The institutional investor owned 5,283 shares of the companys stock after acquiring an additional 1,799 shares during the quarter. Royal Bank of Canadas holdings in Penumbra were worth $1,448,000 as of its most recent filing []

Zacks Investment Research upgraded shares of Penumbra (NYSE:PEN) from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The companys portfolio of products primarily addresses neuro and peripheral vascular medical conditions [] The post Penumbra (NYSE:PEN) Lifted to Hold at Zacks Investment Research appeared first on ETF Daily News .

Neurovascular intervention is the use of minimally invasive medical devices and techniques to treat vascular diseases of central nervous system. Neurovascular interventional procedures help to avoid surgeries of high-risk zones of body such as brain, spine, or the neck. The Global

Zacks Investment Research downgraded shares of Penumbra (NYSE:PEN) from a hold rating to a sell rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The companys portfolio of products primarily addresses neuro and peripheral vascular medical conditions []

Comerica Bank cut its holdings in Penumbra, Inc. (NYSE:PEN) by 1.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,592 shares of the companys stock after selling 320 shares during the quarter. Comerica Bank owned about 0.05% of Penumbra worth $4,745,000 as of its most recent []

Equities research analysts expect Penumbra, Inc. (NYSE:PEN) to report earnings per share of $0.19 for the current quarter, Zacks reports. Three analysts have made estimates for Penumbras earnings, with the highest EPS estimate coming in at $0.24 and the lowest estimate coming in at $0.16. Penumbra posted earnings of $0.42 per share during the same []

Penumbra found using ticker (PEN) now have 6 analysts covering the stock with the consensus suggesting a rating of ''Strong_Buy''. The target price ranges between 350 and 308 calculating the mean target price we have 329.83. With the stocks previous close at 266.51 this would indicate that there is a potential upside of 23.8%. The 50 day MA is 272.53 while the 200 day moving average is 271.15. The company has a market capitalisation of $9,720m. Find out more information at: /> [stock_market_widget type="chart" symbol="PEN" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Penumbra designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands.

Bank of America Corp DE cut its position in Penumbra, Inc. (NYSE:PEN) by 4.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,220 shares of the companys stock after selling 3,264 shares during the period. Bank of America Corp []

Related Stocks: ARGX , MGNX , CUTR , RNA , FULC , ITOS , TMO , PEN , TNYA , SGHT , AADI , RCOR , QDEL , TRIL , CHAQ , BCTG , ITMR , RACA ,

Comprehensive business-related information is covered in the Mechanical Thrombectomy Devices market report such as price level, market trend, demand, supply and price index. It provides only market related data. It does not include any personal data. Another main goal of

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q3 2021 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of -14.29% and 4.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

New York, New York--(Newsfile Corp. - September 21, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN). Such investors a